Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report

Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer. Since this time, however, few case reports outlining real-world usage have been published in the literature. Here, we detail the clinical history of an elderly woman with KRAS wild-type colon cancer who received regora...

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer

PURPOSE Regorafenib, an oral multikinase inhibitor, has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients that have progressed after all standard therapies. However, novel strategies to improve tolerability and enhance anti-cancer efficacy are needed. EXPERIMENTAL DESIGN We have evaluated in vitro the effects of regorafenib in combination with silybin, a biological...

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report

BACKGROUND Regorafenib is an oral multikinase inhibitor that has been demonstrated as clinically effective in patients with metastatic colorectal cancer in phase III studies. Although disease control was achieved in 40% of the pretreated patients with metastatic colorectal cancer in the pivotal studies, radiological response has rarely been reported. Severe adverse events associated with regora...

Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management

Regorafenib is a broad-spectrum oral multikinase inhibitor that targets several angiogenic, oncogenic, and stromal receptor tyrosine kinases that support the tumor microenvironment. Results from the pivotal Phase III Patients with Metastatic Colorectal Cancer Treated with Regorafenib or Placebo After Failure of Standard Therapy (CORRECT) trial showed that the addition of regorafenib to best sup...